Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia ...

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic ...

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at ...

Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b study of R2891, a ...

Charlie Smith. Poster exhibit. Case of Fetal Immature Trauma. The Southern Radiological Conference, Marriott's Grand Hotel, Resort and Spa, Point Clear, Alabama, January 25-27, 2013. Charlie Smith.

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced updated preclinical data from the company’s ...

A poster session December 7, 2014, at the 56th Annual Meeting of the American Society of Hematology in San Francisco was dedicated to trials evaluating therapeutic options in chronic myelogenous ...

SAN FRANCISCO--(BUSINESS WIRE)--Concentric Analgesics, Inc. today announced the poster presentation of clinical data for vocacapsaicin, its first-in-class non-opioid lead product candidate for the ...